Turinabol 10mg/tab 100 Tabletten by Rossiaz Lab

Usage

1. Confirm baseline liver function (ALT, AST) and lipid panel before initiating Turinabol in any bulking protocol.
2. Begin at 20 mg daily (two 10 mg tablets) split across morning and early afternoon to distribute plasma levels across training and recovery windows.
3. Administer each dose with a moderate-calorie meal containing protein and complex carbohydrates to support the anabolic environment and maintain GI comfort.
4. Escalate to 30 mg daily from week three if tolerance is confirmed; pair with your established long-ester injectable testosterone base for a synergistic bulk-phase anabolic environment.
5. Repeat ALT/AST blood work at week four; use results to decide whether to maintain current dose, step to 40 mg, or initiate step-down ahead of schedule.
6. Complete a structured PCT with a SERM (e.g. Nolvadex or Clomid) commencing within one week of the final oral tablet, and continue the injectable base taper according to ester half-life.

Warnings

Frequently asked questions

Is Chlordehydromethyltestosterone from Rossiaz Lab an effective compound for off-season bulking cycles?

Yes — Chlordehydromethyltestosterone is well-suited to off-season bulking because it drives nitrogen retention and lean tissue accrual during a caloric surplus without the estrogenic water retention associated with Methandienone or Oxymetholone. Practitioner-reported bulk protocols document meaningful strength and dry-mass gains at 20–40 mg daily, making it a preferred oral for athletes who prioritise quality of mass over total scale of weight gain.

How should daily Turinabol dose be structured when running it through an entire bulk phase?

Most bulk-phase protocols begin at 20 mg daily for the first two weeks to establish tolerance, escalate to 30 mg daily from week three onward, and optionally reach 40 mg daily in the peak accumulation window if liver enzyme monitoring (ALT/AST at week four) remains within acceptable range. Splitting the total daily dose across morning and early-afternoon administrations distributes plasma availability across both training and post-workout recovery periods.

What injectable compounds pair most rationally with Turinabol during a lean bulk?

Long-ester testosterone, specifically Testosterone Enanthate or Cypionate at 300–500 mg weekly, is the most frequently documented injectable base alongside oral Chlordehydromethyltestosterone in bulk-phase protocols. The oral compound contributes immediate androgen receptor engagement while the long-ester injectable builds to steady-state over weeks two through four, producing a complementary dual-phase anabolic environment through the early bulk window.

Why does the 10 mg per tablet format offer a practical advantage over higher-concentration Turinabol tablets in a bulking protocol?

The 10 mg tablet is the lowest per-unit concentration available in this compound category, which means dose escalation or reduction during a bulk can occur in the smallest meaningful increment — a single tablet — without cutting. Higher-concentration tablets (20 mg or 25 mg) require splitting to achieve the same flexibility, introducing gravimetric dose error that undermines the precision needed when adjusting intake against ongoing liver enzyme data.

How many tablets does the 100-tab Rossiaz Lab pack cover across a standard bulk cycle, and is a single pack sufficient?

At 20 mg daily, the 100-tablet pack covers 50 days of uninterrupted use — a complete seven-week bulk phase. At 30 mg daily, supply extends to approximately 33 days, suitable as a six-week opening block within a longer injectable cycle. A single 100-tablet pack is typically sufficient for a structured oral bulking phase of four to seven weeks depending on the chosen daily dose. (2) angle_used

Manufacturer

Rossiaz Lab's approach to oral tablet production is defined by one specific engineering priority that directly benefits the end user of a low-concentration product: excipient matrix homogeneity. For Turinabol 10mg/tab, the 10 mg API quantity represents a proportionally small mass relative to the total tablet weight — meaning that any non-uniform distribution of Chlordehydromethyltestosterone through the binder and filler matrix during granulation creates a disproportionate per-tablet dose deviation. Rossiaz Lab addresses this through tightly controlled wet-granulation parameters at the blending stage, using pharmaceutical-grade microcrystalline cellulose as the primary filler and povidone as the binding agent, with API homogeneity verified by content-uniformity sampling before compression. Finished tablets from each production run are then submitted to reversed-phase HPLC potency quantification and LAL endotoxin screening — dual-assay release criteria that ensure the declared 10 mg per tablet reflects a physically consistent, analytically confirmed reality across the full 100-tablet pack.